10.1007/s00262-022-03302-5 - Nivolumab versus placebo as adjuvant ...

This document has been corrected

Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival

10.1007/s00262-022-03302-5

Published Online: 2022-10-05

Journal: Cancer Immunology, Immunotherapy•Publisher: Springer Science and Business Media LLC

Authors: Alexander N. Shoushtari•Brian D. Stwalley•Ella X. Du•Jeffrey S. Weber•Keith A. Betts•Leon A. Sakkal•Tayla Poretta•Travis Wang•Yan Chen•Yan Wang

This document has been corrected

10.1007/s00262-022-03302-5

Published Online: 2022-10-05

Journal: Cancer Immunology, Immunotherapy

Authors: Alexander N. Shoushtari•Brian D. Stwalley•Ella X. Du•Jeffrey S. Weber•Keith A. Betts•Leon A. Sakkal•Tayla Poretta•Travis Wang•Yan Chen•Yan Wang

NOW

2022-12-20•Correction

Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival

10.1007/s00262-022-03351-w

* information provided by CrossRef

2022-12-20•Correction

10.1007/s00262-022-03351-w

* information provided by CrossRef

2022-10-05•Published

2022-12-20•Correction

10.1007/s00262-022-03351-w

* information provided by CrossRef

This document has been corrected

10.1007/s00262-022-03302-5

Published Online: 2022-10-05

Journal: Cancer Immunology, Immunotherapy•Publisher: Springer Science and Business Media LLC

Authors: Alexander N. Shoushtari•Brian D. Stwalley•Ella X. Du•Jeffrey S. Weber•Keith A. Betts•Leon A. Sakkal•Tayla Poretta•Travis Wang•Yan Chen•Yan Wang